Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Sunshine Biopharma (SBFM) over the last 12 years, with Q3 2025 value amounting to $65355.0.

  • Sunshine Biopharma's Non Operating Income fell 4719.51% to $65355.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$33399.0, marking a year-over-year decrease of 10417.14%. This contributed to the annual value of $443147.0 for FY2024, which is 3429.22% down from last year.
  • Per Sunshine Biopharma's latest filing, its Non Operating Income stood at $65355.0 for Q3 2025, which was down 4719.51% from $74655.0 recorded in Q2 2025.
  • Sunshine Biopharma's Non Operating Income's 5-year high stood at $946747.0 during Q4 2021, with a 5-year trough of -$4.9 million in Q1 2021.
  • For the 5-year period, Sunshine Biopharma's Non Operating Income averaged around -$431485.2, with its median value being $89141.0 (2024).
  • As far as peak fluctuations go, Sunshine Biopharma's Non Operating Income crashed by 858012.73% in 2021, and later soared by 144282.05% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Non Operating Income (Quarter) stood at $946747.0 in 2021, then crashed by 91.06% to $84599.0 in 2022, then skyrocketed by 86.13% to $157464.0 in 2023, then plummeted by 258.28% to -$249227.0 in 2024, then skyrocketed by 126.22% to $65355.0 in 2025.
  • Its Non Operating Income stands at $65355.0 for Q3 2025, versus $74655.0 for Q2 2025 and $75818.0 for Q1 2025.